Tag: NASDAQ:NMRD

August 7, 2019

Nemaura Announces First SugarBEAT Device Shipments

Nemaura Medical (NASDAQ:NMRD) has announced the first shipments of its SugarBEAT devices to diabetic and prediabetic patients in the United...
May 29, 2019

Nemaura Notches CE Mark for SugarBEAT

With the CE Mark approval, Nemaura Medical will be able to sell its SugarBEAT device across the European Union.
May 29, 2019

Nemaura Receives CE Mark Approval of SugarBEAT

Nemaura Medical (NASDAQ:NMRD) has announced it has received CE Mark approval for SugarBEAT, a non-invasive device for diabetics and pre-diabetics....
February 12, 2019

Nemaura Reports Third Quarter 2018 Financial Results

Nemaura Medical (NASDAQ:NMRD) has announced its financial results for Q3 ended December 30, 2018. As quoted in the press release:...
December 18, 2018

Nemaura Publishes Positive Data from SugarBEAT FDA Clinical Trial

Nemaura Medical (NASDAQ:NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for...
December 18, 2018

Nemaura Medical Announces Pricing of Up to $2.5 Million Public Offering

Nemaura Medical (NASDAQ:NMRD), a medical technology company developing sugarBEAT as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for...
December 6, 2018

Medical Device Trends 2018: M&A, Tech and Regulatory Impact

With 2018 coming to a close, here the Investing News Network takes a look at the biggest medical device trends...